Halozyme Therapeutics (HALO) Share-based Compensation (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Share-based Compensation of $170000.0 for Q1 2026, down 98.41% year-over-year from $10.7 million in Q1 2025, and down 99.67% quarter-over-quarter from $51.1 million in Q4 2025.
Halozyme Therapeutics (HALO) Share-based Compensation (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Share-based Compensation for 17 consecutive years, with $170000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 98.41% year-over-year to $170000.0; the TTM figure through Mar 2026 stood at $41.1 million (down 23.35% YoY), while the FY2025 annual figure was $51.6 million, up 18.85% from the prior year.
- Share-based Compensation eased to $170000.0 in Q1 2026 per HALO's latest filing, from $51.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $51.1 million in Q4 2025 and bottomed at -$9.9 million in Q2 2025.
- Historically, Share-based Compensation has averaged $7.8 million across 5 years, with a median of $753000.0 in 2022.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 17404.02% — and 2025, when it slumped 1117.5%.
- Halozyme Therapeutics' Share-based Compensation stood at $33.5 million in 2022, then plunged by 95.93% to $1.4 million in 2023, then surged by 742.17% to $11.5 million in 2024, then surged by 346.17% to $51.1 million in 2025, then slumped by 99.67% to $170000.0 in 2026.
- Business Quant data shows HALO's Share-based Compensation at $170000.0 in Q1 2026, $51.1 million in Q4 2025, and -$307000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 17.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.70 Mn |
| Jun 30, 2026 | 17.70 Mn |
| Mar 31, 2026 | 170,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 51.14 Mn |
| Dec 31, 2025 | 51.14 Mn |
| Sep 30, 2025 | -307,000.00 |
| Sep 30, 2025 | -307,000.00 |
| Jun 30, 2025 | -9.94 Mn |
| Jun 30, 2025 | -9.94 Mn |
| Mar 31, 2025 | 10.67 Mn |
| Mar 31, 2025 | 10.67 Mn |
| Dec 31, 2024 | 11.46 Mn |
| Dec 31, 2024 | 11.46 Mn |
| Sep 30, 2024 | 30.46 Mn |
| Sep 30, 2024 | 30.46 Mn |
| Jun 30, 2024 | 977,000.00 |
| Jun 30, 2024 | 977,000.00 |
| Mar 31, 2024 | 489,000.00 |
| Mar 31, 2024 | 489,000.00 |